Stock Evaluator: TG Therapeutics, Inc. (TGTX)

TG Therapeutics, Inc. TGTX

$52.03 -1.50 -2.80%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 2,489,356
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Commentary & Analysis


Financial Summary

Share Statistics TGTX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $7,576.5 $251.9 73%
Shares Out (Mil) 160.1 50.8 72%
Institutional Ownership 94.4% 92.0% 65%
Float (Mil) 135.1 40.5 67%
Beta 1.60 0.95 85%
Avg Daily Volume (000s) 2,143 447 83%
Price Change
(52-week)
51.3% 54.2% 81%
Growth TGTX Industry
Median
Percentile
(All Stocks)
Sales (5yr) 398.6% 14.0% 100%
Net Income (5yr) 29.2% (9.8%) 84%
EPS (5yr) 25.7% 16.3% 76
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (16.9%) (15.6%) 42%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 5 6 6
Current EPS $0.439 $1.572 $3.281
Month Ago EPS $0.427 $1.535 $2.872
# Rev Up 1 1 0
# Rev Down 0 0 1
Three Months Ago EPS $0.319 $1.265 $2.407
Year/Year Chg 265.8% (43.2%) 34.5%
Financials TGTX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $700 $39 46%
Net Income (TTM) (Mil) $462 ($43) 78%
EPS (TTM) $3.213 ($1.600) 80%
Operating Cash Flow (TTM) (Mil) ($14) ($30) 17%
Net Cash Flow (TTM) (Mil) $310 $3 88%
Long-Term Debt (Q1) (Mil) $752 $5 63%
Enterprise Value (Q1) (Mil) $8,234 $182 71%
Valuation TGTX Industry
Median
Percentile
(All Stocks)
P/B 13.01 2.60 92%
P/E 18.6 18.6 46%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 0.7 0.9 34%
Ratios TGTX Industry
Median
Percentile
(All Stocks)
Gross Margin 83.1% 63.8% 90%
Net Margin 66.0% (64.7%) 98%
ROA 42.3% (49.7%) 99%
ROE 112.6% (55.4%) 96%
Liabilities to Assets 61.9% 30.3% 56%
F-Score 4 3 na

Passing Stock Screens

As of 7/30/2026, from a list of 60 stock screening strategies, TGTX meetings the criteria of 1 screen:

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors